Khartis Therapeutics has secured $50 million in Series B funding, led by Forge Life Science Partners with participation from Longwood Fund and Alexandria Venture Investments. This follow-on round brings the company's total capital raised to an unspecified amount. The funds will be used to advance Khartis' pipeline of oral small molecule medicines for immunological and chronic diseases.